Sunday, June 10, 2012

More FB Fallout

Several mutual funds that invest in private companies such as Facebook have taken extreme hits due to the 29% decrease in FB stock price since the IPO. This will likely impact the future investments made by these so-called "business development companies." Media reports show that GSV Capital has a FB allocation of just 3.8%, yet GSV's share price has dropped more than 35% since the FB IPO. Ditto Firsthand Technology Value fund with its 7% allocation of FB and a nearly 32% drop in its share price since the IPO. The drop in FB shares has also impacted other large private companies such as Twitter, down about 15% since before the FB IPO. We should all hope that FB shares recover!

Thursday, May 24, 2012

Lessons from Facebook

By now we all have heard about FB's "disastrous" IPO,with the stock price sinking more than 15% since it opened last Friday. Financially, in the short term, FB and its existing investors came out quite nicely in the deal, however. They were able to get 15% more when they sold their stock than what those who purchased it from them can now get for the same item. This is akin to the "Buy low, sell high" mantra of making money, and we all know that works quite well. In the long run, however, FB and the other sellers of FB stock that still retain ownership may end up wishing they had not made so much money off of those who purchased from them last Friday. The very public black eye for the very public company may do far more damage over the long haul than was made on that one day. This will be quite interesting to watch...

Monday, May 07, 2012

Crowdsourcing Drug Development

Crowdsourcing has proven highly effective in bringing many minds to bear on a range of problem to be solved, though often for issues as simple as a logo design. That power of course can be brought to bear on problems far more complex. The National Institutes of Health, following the lead of a program begun in Great Britain, will begin on October 1 providing grants to researchers to allow them to attempt to find new uses for drugs abandoned as ineffective for their original intent by companies such as Eli Lilly, Pfizer, and AstraZeneca. History has shown that some drugs found ineffective for treating the ailment originally targeted can be highly effective against other conditions. The drug AZT is one such drug, originally designed for cancer but now used against AIDS. NIH is making $20 million available in grants for researching new uses for about 20 drugs initially, but hopes to expand the program. Persons conducting this research will have the benefit of millions of dollars already expended by the major companies to determine, for instance, safe dosage levels. Sounds like a win-win-win to me. The program is being run by NIH's new National Center for Advancing Translational Sciences.